文献速递临床试验与 GCP基础与转化研究

富血小板血浆治疗跟腱愈合2(PATH-2)试验:多中心、双盲、平行组、安慰剂对照随机临床试验的统计分析计划

Platelet-rich plasma in Achilles tendon healing 2 (PATH-2) trial: statistical analysis plan for a multicentre, double-blinded, parallel-group, placebo-controlled randomised clinical trial.
PubMed 文献 · Trials · 2018-08-29

PATH-2试验是一项实用型、多中心、双盲、随机、安慰剂对照的优势试验,旨在评估富血小板血浆(PRP)对急性跟腱断裂患者肌肉-肌腱功能的临床疗效。主要结局为随机化后24周时提踵耐力测试得出的肌肉-肌腱做功能力(以肢体对称指数表示,单位焦耳)。本文件描述了该试验的统计分析计划(SAP),包括主要分析采用改良意向性分析、多变量线性回归调整分层因素和预后因素,并计划进行符合方案分析作为敏感性分析。

要点

  • PATH-2试验评估PRP对急性跟腱断裂患者肌肉-肌腱功能的疗效,主要结局为24周时提踵耐力测试的肢体对称指数(做功,焦耳)。
  • 主要分析采用改良意向性分析,多变量线性回归调整中心、年龄等分层因素和预后因素。
  • 敏感性分析采用符合方案分析评估内部有效性,安全性在所有开始治疗的患者中按治疗组汇总。

核心结论

  • PATH-2试验的统计分析计划已制定,将按照CONSORT声明报告结果,以避免因预先知晓研究结果而产生的偏倚。

研究设计与样本

  • PATH-2是一项实用型、平行组、多中心、双盲、随机、安慰剂对照的优势试验,研究对象为骨科/创伤门诊识别的急性跟腱断裂患者。

关键数值与推荐

  • 主要结局为随机化后24周时提踵耐力测试得出的肌肉-肌腱做功能力,以肢体对称指数(做功,单位焦耳)表示。
  • 主要分析采用多变量线性回归调整分层因素(中心和年龄)及额外预后因素,分析基于改良意向性分析。
  • 敏感性分析将进行符合方案分析以评估试验结果的内部有效性。
  • 安全性将在所有开始治疗的患者中按治疗组进行汇总。
  • 次要患者报告结局指标将采用线性混合效应模型分析,以考虑所有随访时间点收集的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been a recent steep growth in platelet-rich plasma (PRP) use for musculoskeletal conditions, but findings from high quality clinical trial data are lacking in the literature. Here, we describe the statistical analysis plan (SAP) for the Platelet-rich plasma in Achilles Tendon Healing 2 (PATH-2) trial. METHODS: PATH-2 is a pragmatic, parallel-group, multi-centre, double-blinded, randomised, placebo-controlled, superiority trial. The study aims to evaluate the clinical efficacy of PRP in acute Achilles tendon rupture in terms of muscle-tendon function. Patients are identified in the orthopaedic/trauma outpatient clinic. The primary outcome is muscle-tendon work capacity from the Heel Rise Endurance Test result, expressed as the Limb Symmetry Index (work, in joules), at 24 weeks post randomisation. Multivariate linear regression adjusting for the stratification factors (centre and age) and additional prognostic factors will be used to investigate the adjusted effect of the intervention. The analysis will be by modified intention-to-treat. Sensitivity analysis will assess the internal validity of the trial results by performing a per-protocol analysis. Safety will be summarised by treatment arm for all patients who started treatment. Secondary patient-reported outcome measures will be analysed using linear mixed effects models to allow all data collected at all follow-up points to be considered. Missing data will be summarised and reported by treatment arm. Missing data imputation will be performed, if appropriate. DISCUSSION: The PATH-2 trial will be reported in accordance with the CONSORT statement. This SAP publication will avoid bias arising from prior knowledge of the study results. Any changes or deviations from the current SAP will be described and justified in the final report. TRIAL REGISTRATION: ISRCTN registry: ISRCTN54992179 , assigned 12 January 2015. ClinicalTrials.gov: NCT02302664, received 18 November 2014. UK Clinical Research Network Study Portfolio Database: ID 17850.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Schlüssel MM, Keene DJ, Wagland S, et al. Platelet-rich plasma in Achilles tendon healing 2 (PATH-2) trial: statistical analysis plan for a multicentre, double-blinded, parallel-group, placebo-controlled randomised clinical trial. Trials. 2018. PMID: 30157940. doi:10.1186/s13063-018-2840-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。